Researchers at University College London have identified a protein called LRG1 as the earliest trigger of diabetic retinopathy, the leading cause of blindness among working-age adults worldwide. The groundbreaking findings, published on March 7, 2026, in the journal Science Translational Medicine, reveal that LRG1 constricts retinal blood vessels, reducing blood flow and initiating the cascade of damage that ultimately leads to vision loss in people with diabetes. The discovery represents a potential paradigm shift in ophthalmology, moving from treating late-stage damage to preventing the root cause before any vision impairment occurs.
Diabetic retinopathy affects approximately 100 million people globally and has long been one of the most devastating complications of diabetes. Until now, the precise mechanism that initiates the disease process remained poorly understood. Existing treatments, including laser therapy and anti-VEGF injections, are only effective at advanced stages when abnormal blood vessel growth has already caused significant and often irreversible damage to the retina. Patients frequently experience substantial vision loss before any intervention can begin.
The UCL research team discovered that LRG1 acts at the very earliest stage of diabetic retinopathy, well before the abnormal blood vessel proliferation that characterizes advanced disease. The protein triggers vasoconstriction in retinal blood vessels, choking off the blood supply to delicate retinal tissue. This reduced blood flow causes progressive damage to the retinal cells responsible for vision, setting off a chain of pathological events that eventually leads to the hallmark signs of the disease. The identification of this initial trigger provides an entirely new target for therapeutic intervention.
In a particularly promising development, a drug specifically designed to block the activity of LRG1 has already been developed and is ready to enter clinical trials. The therapeutic agent works by neutralizing the protein before it can constrict retinal blood vessels, thereby preserving normal blood flow and preventing the earliest damage from occurring. If successful in human trials, the drug could fundamentally change the treatment landscape for diabetic retinopathy, offering patients a preventive option rather than relying on interventions that address damage after it has already occurred.
Experts in ophthalmology and diabetes research have described the findings as a major breakthrough with far-reaching implications. The ability to intervene at the earliest stage of the disease could prevent blindness in millions of people living with diabetes around the world. Rather than waiting for patients to develop visible retinal damage and significant vision loss, physicians could potentially administer the LRG1-targeting therapy as a preventive measure for at-risk individuals, transforming diabetic retinopathy from a progressive blinding condition into a manageable complication.
The discovery also carries broader implications beyond diabetic retinopathy. Since LRG1 affects vascular function through its action on blood vessels, the protein may play a role in other vascular diseases throughout the body. Researchers at UCL have indicated that future studies will explore the potential connection between LRG1 and conditions such as cardiovascular disease, kidney disease, and other complications associated with diabetes. The clinical trials for the LRG1-targeting drug are expected to begin enrollment in the coming months, with researchers expressing optimism about the potential to bring a transformative therapy to patients within the next several years.
Comments